Cyanotech (CYAN) Q3 2025 earnings summary

Executive summary

• Net sales for Q3 FY2025 increased 10.6% year-over-year to $6.2 million, driven by higher bulk sales and contract extraction revenue, offset by lower packaged astaxanthin sales.

• Gross profit margin improved to 35.3% from 29.5% in the prior year quarter due to higher production volumes and lower costs.

• Operating loss narrowed to $50,000 from $848,000 in the prior year quarter; net loss was $224,000, or $(0.03) per share.

• For the nine months ended December 31, 2024, net sales rose 4.8% to $17.9 million, but gross profit margin declined to 28.7% from 30.8% due to higher costs in the first half.

• The company continues to face liquidity challenges and substantial doubt about its ability to continue as a going concern.

Financial highlights

• Q3 FY2025 net sales: $6.2 million (+10.6% YoY); nine months: $17.9 million (+4.8% YoY).

• Q3 gross profit: $2.2 million (35.3% margin); nine months: $5.1 million (28.7% margin).

• Q3 operating loss: $50,000; nine months: $2.1 million.

• Q3 net loss: $224,000 ($(0.03)/share); nine months: $2.6 million ($(0.37)/share).

• Cash at December 31, 2024: $359,000; working capital: $602,000.

Outlook and guidance

• Focus remains on stabilizing production, rationalizing market channels, and leveraging core competencies.

• Emphasis on higher-margin consumer products and bulk sales, with continued cost control and process improvements.

• Gross margin may face pressure from lower production volumes, input costs, and increased competition.

• No specific quantitative guidance provided; management notes significant sales variability may occur.